Takeda Inks $2.2 Billion License Deal for AC Immune’s Alzheimer’s Immunotherapy
Takeda has secured an exclusive global option and license agreement for AC Immune’s promising active immunotherapy targeting amyloid beta for
Read moreTakeda has secured an exclusive global option and license agreement for AC Immune’s promising active immunotherapy targeting amyloid beta for
Read moreAmerican multinational pharmaceutical company Bristol Myers Squibb and Karuna Therapeutics, Inc. (“Karuna”) have announced that they have entered into a
Read moreAlzheimer’s disease (AD) and Parkinson’s disease (PD) stand as the two most prevalent neurodegenerative disorders, each characterized by the cerebral
Read moreIn the neurobiology landscape, the Tau protein plays a crucial role in stabilizing microtubules within neurons. Positioned primarily in axons
Read moreStressMarq Biosciences, a market leader and pioneer in the field of fibrilized and oligomeric protein preparations for neurodegenerative disease research,
Read moreIn a recent scientific commentary, Brenda Knox at StressMarq delves into the complex interplay between amyloid-beta plaques and tau neurofibrillary
Read moreResearchers have devised a novel human 3D model for Alzheimer’s Disease, enabling the study of immune cell involvement in the
Read moreSeelos Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in therapies for central nervous system disorders and rare diseases, has unveiled
Read moreStressMarq manufactures and offers a comprehensive range of Alzheimer’s Disease Research Products. StressMarq’s product range includes Antibodies, Proteins, Immunoassays, Small
Read moreStressMarq Biosciences, a leading provider of cutting-edge neurodegenerative disease research products, is thrilled to announce its participation in the Alzheimer’s
Read more